Research output per year
Research output per year
Search results
-
2024
Artificial Intelligence Technologies for Assessing Skin Lesions for Referral on the Urgent Suspected Cancer Pathway to Detect Benign Lesions and Reduce Secondary Care Specialist Appointments: Early Value Assessment
Walton, M. J., Llewellyn, A., Uphoff, N., Lord, J., Harden, M., Hodgson, R. & Simmonds, M. C., 28 Aug 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia
Deng, J., Corbett, M. S., Uphoff, N., Lord, J., Fulbright, H., Griffin, S., Rothery, C. & Hodgson, R., 2 Aug 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer
Corbett, M. S., Deng, J., Uphoff, N., Walton, M. J., Lord, J., Fulbright, H. A., Dwan, K. & Hodgson, R., 7 Feb 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688)
Uphoff, N., Lord, J., Anwer, S., Harden, M., Baker, M., Walton, M. J. & Nevitt, S. J., 3 Jul 2024, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
2023
Cipaglucosidase alfa with miglustat for treating Pompe disease
Wade, R., Deng, J., Dwan, K., Robertson, L., Uphoff, N., Fulbright, H. A., Dias, S., Hodgson, R. & Eastwood, A. J., 15 Aug 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Walton, M. J., Corbett, M. S., Dwan, K., Njoroge, M. W., Fulbright, H. A., Uphoff, N., Hodgson, R. & Dias, S., 11 May 2023, National Institute for Health and Care Excellence.Research output: Book/Report › Commissioned report
-
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. External Assessment Group Report
Saramago Goncalves, P. R., Rodgers, M., Premji, S., Uphoff, N., Gao, M., Fulbright, H. A., Duarte, A. I. & Simmonds, M. C., 17 Oct 2023Research output: Book/Report › Commissioned report